Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency

Neurology. 2004 Oct 26;63(8):1524-6. doi: 10.1212/01.wnl.0000142083.47927.0a.

Abstract

The authors report the long-term course of two siblings with L-dopa responsive dystonia (DRD) associated with a compound heterozygous mutation in the tyrosine hydroxylase (TH) gene. Both siblings manifested with lower-limb onset generalized DRD and had a sustained response to low-dose L-dopa therapy for over 35 years. Although the l-dopa therapy was delayed up to 20 years after disease onset, there were no cognitive or neurologic sequelae of the long-term catecholamine deficit.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Age of Onset
  • Brain / enzymology
  • Brain / pathology
  • Brain / physiopathology
  • Brain Chemistry / genetics*
  • Catecholamines / biosynthesis
  • Catecholamines / deficiency*
  • DNA Mutational Analysis
  • Disease Progression
  • Dopamine Agents / adverse effects
  • Dopamine Agents / therapeutic use
  • Dystonia / drug therapy
  • Dystonia / enzymology*
  • Dystonia / genetics
  • Heterozygote
  • Humans
  • Levodopa / adverse effects
  • Levodopa / therapeutic use*
  • Longitudinal Studies
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Panic Disorder / chemically induced
  • Point Mutation / genetics*
  • Siblings
  • Time
  • Tyrosine 3-Monooxygenase / deficiency*
  • Tyrosine 3-Monooxygenase / genetics

Substances

  • Catecholamines
  • Dopamine Agents
  • Levodopa
  • Tyrosine 3-Monooxygenase